GENE ONLINE|News &
Opinion
Blog

2020-03-05| Trials & Approvals

Kainos Medicine’s New HIV Drug Kicks Off Phase III Trial in China

by GeneOnline
Share To

As a drug developing company, Korea-based Kainos Medicine focuses on discovering safe and effective molecules for treating brain diseases, infectious diseases, and cancers. Positioning itself as a new drug developing platform, Kainos Med in surveying new drug candidates and evaluates the possibility of the molecule until early-stage clinical trial. The potential candidate drugs are then transferred to domestic or foreign pharma groups for pursuing regulatory approval and initiate commercial production.

Kainos’ latest achievement is that its anti-HIV molecule, KM023, which was transferred to Jiangsu Aidea Pharmaceuticals and was designated a fast-track review by the CFDA in 2016, has entered phase III clinical trial. KM023 is a Non-nucleoside reverse transcriptase inhibitor (NNRTI), which performs antiretroviral activity by blocking the reverse transcriptase enzyme. Sharing the same mechanism with HIV medication Sustiva (efavirenz) from Bristol-Myers Squibb, KM023 was designed as a better alternative with fewer side effects.

In the phase I trial, KM023 has been proved to be safe and as effective as existing treatment with only a quarter of the dosage, which made it possible for the drug to be compacted with other molecules into one pill. As the demand for new drugs is soaring, the Chinese government has put emphasis on drug development and commercialization to provide faster and cheaper medication for all. As a result, KM023 is included in its pharmaceutical innovation project. Aidea Pharmaceuticals is now conducting the phase III trial of KM023 in China with the support of the local government, and the results should be presented before July this year. So far, the tests are going smoothly, a company official claimed.

Kainos Med has made a $170 million profit by transferring its technology to Aidea Pharmaceuticals and will receive a 2% royalty income for every deal of the KM023 agent. As Aidea pharmaceuticals expect KM023 to take up 30% of the Chinese anti-HIV drug market upon release, the royalty income and global sales rights of Kainos Med could create a huge wealth in the near future.

Related article: A re-challenge of Kangstem Biotech’s new stem cell drug against Atopic dermatitis

References
  1. http://kainosmedicine.com/
  2. http://www.aidea.com.cn/ptindex.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions
2022-11-08
Bristol Myers Squibb Releases Promising Preliminary Anemia Clinical Trial Results
2022-10-31
Kura Oncology Boasts Immunotherapy Preliminary Trial Data Success
2022-10-26
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!